Jonathan M Raviotta
Overview
Explore the profile of Jonathan M Raviotta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nowalk M, Smith K, Raviotta J, Wateska A, Zimmerman R
Vaccine
. 2024 Jul;
42(24):126107.
PMID: 38971665
Background: The Advisory Committee on Immunization Practices (ACIP) uses the Evidence to Recommendations Framework that includes cost-effectiveness analyses (CEA) for determining vaccine recommendations. ACIP's preference for protecting adults ≥ 65 ...
2.
Zimmerman R, Nowalk M, Dauer K, Clarke L, Raviotta J, Balasubramani G
Vaccine
. 2023 Jul;
41(35):5134-5140.
PMID: 37474406
Background: Relative effectiveness of various vaccine formulations provide important input for vaccine policy decisions and provider purchasing decisions. We used electronic databases to conduct a test-negative case control study to...
3.
Zimmerman R, Dauer K, Clarke L, Nowalk M, Raviotta J, Balasubramani G
Hum Vaccin Immunother
. 2023 Feb;
19(1):2177461.
PMID: 36809982
Newer influenza vaccine formulations have entered the market, but real-world effectiveness studies are not widely conducted until there is sufficient uptake. We conducted a retrospective test-negative case-control study to determine...
4.
Krauland M, Zimmerman R, Williams K, Raviotta J, Harrison L, Williams J, et al.
Vaccine X
. 2022 Dec;
13:100249.
PMID: 36536801
Introduction: Current influenza vaccines have limited effectiveness. COVID-19 vaccines using mRNA technology have demonstrated very high efficacy, suggesting that mRNA vaccines could be more effective for influenza. Several such influenza...
5.
Krauland M, Galloway D, Raviotta J, Zimmerman R, Roberts M
Am J Prev Med
. 2022 Mar;
62(4):503-510.
PMID: 35305778
Introduction: Interventions to curb the spread of COVID-19 during the 2020-2021 influenza season essentially eliminated influenza during that season. Given waning antibody titers over time, future residual population immunity against...
6.
Lee K, Jalal H, Raviotta J, Krauland M, Zimmerman R, Burke D, et al.
Open Forum Infect Dis
. 2022 Jan;
9(1):ofab607.
PMID: 35024374
Background: Influenza activity in the 2020-2021 season was remarkably low, likely due to implementation of public health preventive measures such as social distancing, mask wearing, and school closure. With waning...
7.
Nowalk M, DAgostino H, Zimmerman R, Saul S, Susick M, Raviotta J, et al.
Vaccine
. 2021 Oct;
39(47):6829-6836.
PMID: 34716041
Introduction: Many vaccination studies rely on self-reported vaccination status, with its inherent biases. Accuracy of influenza vaccination self-report has been evaluated periodically, typically using the medical record as the gold...
8.
DePasse J, Nowalk M, Smith K, Raviotta J, Shim E, Zimmerman R, et al.
Hum Vaccin Immunother
. 2019 May;
15(12):2919-2926.
PMID: 31091166
: Broadly protective, long-lasting universal influenza vaccines are under development in response to low-moderate seasonal vaccine effectiveness, frequent genetic changes in circulating viruses and extended turnaround for vaccine manufacture. Because...
9.
Smith K, France G, Nowalk M, Raviotta J, DePasse J, Wateska A, et al.
Am J Prev Med
. 2019 Feb;
56(4):e135-e141.
PMID: 30772149
Introduction: Tradeoffs exist between efforts to increase influenza vaccine uptake, including early season vaccination, and potential decreased vaccine effectiveness if protection wanes during influenza season. U.S. older adults increasingly receive...
10.
France G, Wateska A, Nowalk M, DePasse J, Raviotta J, Shim E, et al.
Innov Aging
. 2018 Dec;
2(3):igy035.
PMID: 30569023
Background And Objectives: "Universal" vaccines that could have multistrain and multiyear effectiveness are being developed. Their potential cost-effectiveness in geriatric populations is unknown. Research Design And Methods: A Markov model...